BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pei H, Guo W, Peng Y, Xiong H, Chen Y. Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Med Res Rev 2022. [PMID: 35312190 DOI: 10.1002/med.21886] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Chen J, Mi D, Ling J, Li H, He P, Liu N, Chen Q, Chen Y, Huang L. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway. Cancer Lett 2023;:216142. [PMID: 36965539 DOI: 10.1016/j.canlet.2023.216142] [Reference Citation Analysis]
2 Gu H, He J, Li Y, Mi D, Guan T, Guo W, Liu B, Chen Y. B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas. J Med Chem 2022;65:15559-83. [PMID: 36441945 DOI: 10.1021/acs.jmedchem.2c01433] [Reference Citation Analysis]
3 Zhang Y, Mi D, Chen Y. An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment. Molecular Therapy - Nucleic Acids 2022;30:351-352. [DOI: 10.1016/j.omtn.2022.10.008] [Reference Citation Analysis]
4 Hasan M, Shawon ARM, Aeyas A, Uddin MA. Cyclic peptides as an inhibitor of metastasis in breast cancer targeting MMP-1: Computational approach. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.101128] [Reference Citation Analysis]
5 He P, Bian A, Miao Y, Jin W, Chen H, He J, Li L, Sun Y, Ye J, Yi Z, Zhou W, Chen Y. Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. J Med Chem 2022. [DOI: 10.1021/acs.jmedchem.2c01554] [Reference Citation Analysis]
6 He P, Miao Y, Sun Y, Bian A, Jin W, Chen H, Ye J, He J, Peng Y, Gu H, Liu M, Yi Z, Chen Y. Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr 705 /Ser 727 Inhibitory Activity for Gastric Cancer Treatment. J Med Chem . [DOI: 10.1021/acs.jmedchem.2c00413] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Pei H, Chen Y. The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma. Clinical and Translational Dis 2022;2. [DOI: 10.1002/ctd2.56] [Reference Citation Analysis]
8 Skuli SJ, Alomari S, Gaitsch H, Bakayoko A, Skuli N, Tyler BM. Metformin and Cancer, an Ambiguanidous Relationship. Pharmaceuticals (Basel) 2022;15. [PMID: 35631452 DOI: 10.3390/ph15050626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Jin W, Zhang T, Zhou W, He P, Sun Y, Hu S, Chen H, Ma X, Peng Y, Yi Z, Liu M, Chen Y. Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis. J Med Chem 2022. [PMID: 35476936 DOI: 10.1021/acs.jmedchem.2c00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]